| Douglas A Bruns, DO | |
|
321 Mitchell Ave, Batesville, IN 47006-8909 | |
| (812) 933-5018 | |
| (812) 933-5472 |
| Full Name | Douglas A Bruns |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 30 Years |
| Location | 321 Mitchell Ave, Batesville, Indiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194724641 | NPI | - | NPPES |
| 940080125 | Other | IN | MEDICARE |
| 200265810 | Medicaid | IN | |
| 0194981 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 34006256B (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Margaret Mary Community Hospital Inc | Batesville, IN | Hospital |
| Christ Hospital | Cincinnati, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Insight Diagnostic Imaging Llc | 4981616893 | 3 |
| Margaret Mary Community Hospital Inc | 5193714335 | 70 |
News Archive
Alaskan native children are experiencing increased rates of serious infections caused by strains of pneumococcal bacteria that are not covered by the current childhood pneumococcal vaccine, indicating the importance of ongoing surveillance of vaccine effectiveness, according to a study in the current issue of JAMA.
Type 1 diabetes, which arises when the pancreas doesn't create enough insulin to control levels of glucose in the blood, is a disease that currently has no cure and is difficult for most patients to manage.
An overwhelming majority of people with incurable cancer want to hear findings from DNA sequencing of their own tumors and normal cells, and to learn how those results may affect their health and treatment options, Dana Farber Cancer Institute scientists report.
ZELTIQ, a California-based developer of ground-breaking non-invasive fat reduction technology, today announces that it has raised $25 million in Series D funding. Aisling Capital led the round and was joined by returning investors Advanced Technology Ventures, Frazier Healthcare Ventures and Venrock. Since being formed in 2005, ZELTIQ has raised approximately $50 million.
› Verified 6 days ago
| Entity Name | Margaret Mary Community Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558368449 PECOS PAC ID: 5193714335 Enrollment ID: O20040511001443 |
News Archive
Alaskan native children are experiencing increased rates of serious infections caused by strains of pneumococcal bacteria that are not covered by the current childhood pneumococcal vaccine, indicating the importance of ongoing surveillance of vaccine effectiveness, according to a study in the current issue of JAMA.
Type 1 diabetes, which arises when the pancreas doesn't create enough insulin to control levels of glucose in the blood, is a disease that currently has no cure and is difficult for most patients to manage.
An overwhelming majority of people with incurable cancer want to hear findings from DNA sequencing of their own tumors and normal cells, and to learn how those results may affect their health and treatment options, Dana Farber Cancer Institute scientists report.
ZELTIQ, a California-based developer of ground-breaking non-invasive fat reduction technology, today announces that it has raised $25 million in Series D funding. Aisling Capital led the round and was joined by returning investors Advanced Technology Ventures, Frazier Healthcare Ventures and Venrock. Since being formed in 2005, ZELTIQ has raised approximately $50 million.
› Verified 6 days ago
| Entity Name | Insight Diagnostic Imaging Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831151083 PECOS PAC ID: 4981616893 Enrollment ID: O20060614000225 |
News Archive
Alaskan native children are experiencing increased rates of serious infections caused by strains of pneumococcal bacteria that are not covered by the current childhood pneumococcal vaccine, indicating the importance of ongoing surveillance of vaccine effectiveness, according to a study in the current issue of JAMA.
Type 1 diabetes, which arises when the pancreas doesn't create enough insulin to control levels of glucose in the blood, is a disease that currently has no cure and is difficult for most patients to manage.
An overwhelming majority of people with incurable cancer want to hear findings from DNA sequencing of their own tumors and normal cells, and to learn how those results may affect their health and treatment options, Dana Farber Cancer Institute scientists report.
ZELTIQ, a California-based developer of ground-breaking non-invasive fat reduction technology, today announces that it has raised $25 million in Series D funding. Aisling Capital led the round and was joined by returning investors Advanced Technology Ventures, Frazier Healthcare Ventures and Venrock. Since being formed in 2005, ZELTIQ has raised approximately $50 million.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Douglas A Bruns, DO Po Box 236, Batesville, IN 47006-0236 Ph: (812) 933-5441 | Douglas A Bruns, DO 321 Mitchell Ave, Batesville, IN 47006-8909 Ph: (812) 933-5018 |
News Archive
Alaskan native children are experiencing increased rates of serious infections caused by strains of pneumococcal bacteria that are not covered by the current childhood pneumococcal vaccine, indicating the importance of ongoing surveillance of vaccine effectiveness, according to a study in the current issue of JAMA.
Type 1 diabetes, which arises when the pancreas doesn't create enough insulin to control levels of glucose in the blood, is a disease that currently has no cure and is difficult for most patients to manage.
An overwhelming majority of people with incurable cancer want to hear findings from DNA sequencing of their own tumors and normal cells, and to learn how those results may affect their health and treatment options, Dana Farber Cancer Institute scientists report.
ZELTIQ, a California-based developer of ground-breaking non-invasive fat reduction technology, today announces that it has raised $25 million in Series D funding. Aisling Capital led the round and was joined by returning investors Advanced Technology Ventures, Frazier Healthcare Ventures and Venrock. Since being formed in 2005, ZELTIQ has raised approximately $50 million.
› Verified 6 days ago
James M Browne Ii, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 321 Mitchell Ave, Batesville, IN 47006 Phone: 513-965-8041 Fax: 513-965-8091 |